JP2005539014A5 - - Google Patents

Download PDF

Info

Publication number
JP2005539014A5
JP2005539014A5 JP2004526380A JP2004526380A JP2005539014A5 JP 2005539014 A5 JP2005539014 A5 JP 2005539014A5 JP 2004526380 A JP2004526380 A JP 2004526380A JP 2004526380 A JP2004526380 A JP 2004526380A JP 2005539014 A5 JP2005539014 A5 JP 2005539014A5
Authority
JP
Japan
Prior art keywords
compound according
alkyl
carbon atoms
heteroaromatic ring
compound
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2004526380A
Other languages
English (en)
Japanese (ja)
Other versions
JP2005539014A (ja
Filing date
Publication date
Priority claimed from US10/212,437 external-priority patent/US6864282B2/en
Application filed filed Critical
Publication of JP2005539014A publication Critical patent/JP2005539014A/ja
Publication of JP2005539014A5 publication Critical patent/JP2005539014A5/ja
Pending legal-status Critical Current

Links

JP2004526380A 2002-08-05 2003-08-04 高眼圧および緑内障処置用のプロスタグランジン類似体の9,11−シクロエンドペルオキシドプロドラッグ Pending JP2005539014A (ja)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US10/212,437 US6864282B2 (en) 2002-08-05 2002-08-05 9,11-cycloendoperoxide pro-drugs of prostaglandin analogues for treatment of ocular hypertension and glaucoma
PCT/US2003/024305 WO2004013119A1 (en) 2002-08-05 2003-08-04 The 9, 11-cycloendoperoxide pro-drugs of prostaglandin analogues for treatment of ocular hypertension and glaucoma

Publications (2)

Publication Number Publication Date
JP2005539014A JP2005539014A (ja) 2005-12-22
JP2005539014A5 true JP2005539014A5 (enExample) 2006-09-28

Family

ID=31187772

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2004526380A Pending JP2005539014A (ja) 2002-08-05 2003-08-04 高眼圧および緑内障処置用のプロスタグランジン類似体の9,11−シクロエンドペルオキシドプロドラッグ

Country Status (9)

Country Link
US (1) US6864282B2 (enExample)
EP (2) EP1527063B1 (enExample)
JP (1) JP2005539014A (enExample)
AT (1) ATE334123T1 (enExample)
AU (1) AU2003261352A1 (enExample)
CA (1) CA2494146A1 (enExample)
DE (1) DE60307106T2 (enExample)
ES (1) ES2268433T3 (enExample)
WO (1) WO2004013119A1 (enExample)

Families Citing this family (16)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7070768B2 (en) * 2003-09-25 2006-07-04 Allergan, Inc. Method for imparting artificial tan to human skin
GB0501192D0 (en) * 2005-01-20 2005-03-02 Resolution Chemicals Ltd Stable prostaglandin-containing compositions
WO2010102078A1 (en) 2009-03-04 2010-09-10 Allergan, Inc. Enhanced bimatoprost ophthalmic solution
US7851504B2 (en) 2005-03-16 2010-12-14 Allergan, Inc. Enhanced bimatoprost ophthalmic solution
US8030349B2 (en) 2005-08-02 2011-10-04 Santen Pharmaceutical Co., Ltd. Method for prevention of degradation of thermally unstable medicament
WO2007111806A2 (en) * 2006-03-23 2007-10-04 Massachusetts Eye And Ear Infirmary Cyclopentane heptanoic acid compounds for reducing body fat
US20110293549A1 (en) 2009-02-03 2011-12-01 Athena Cosmetics, Inc. Composition, method and kit for enhancing hair
US9522153B2 (en) 2009-12-22 2016-12-20 Allergan, Inc. Compositions and methods for lowering intraocular pressure
CA2824317C (en) 2011-01-19 2014-12-16 Terakine Therapeutics, Inc. Uses of certain f-series prostaglandin analogs for treating diabetes and dyslipidemia
US8426471B1 (en) 2011-12-19 2013-04-23 Topokine Therapeutics, Inc. Methods and compositions for reducing body fat and adipocytes
SG11201600237YA (en) 2012-11-21 2016-02-26 Topokine Therapeutics Inc Methods and compositions for locally increasing body fat
NO2753788T3 (enExample) 2013-05-10 2018-06-16
US9820993B2 (en) 2013-05-15 2017-11-21 Topokine Therapeutics, Inc. Methods and compositions for topical delivery of prostaglandins to subcutaneous fat
US9115109B2 (en) * 2013-08-15 2015-08-25 Chirogate International Inc. Processes and intermediates for the preparations of isomer free prostaglandins
WO2015200425A1 (en) 2014-06-27 2015-12-30 Topokine Therapeutics, Inc. Topical dosage regimen
US11571401B2 (en) 2017-09-01 2023-02-07 East Carolina University Compounds, compositions, kits, and methods for activating immune cells and/or an immune system response

Family Cites Families (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4599353A (en) * 1982-05-03 1986-07-08 The Trustees Of Columbia University In The City Of New York Use of eicosanoids and their derivatives for treatment of ocular hypertension and glaucoma
US4867915A (en) * 1986-05-21 1989-09-19 Syntex (U.S.A.) Inc. 16-Substituted polyunsaturated hexadecanoic fatty acids
DE68929435T2 (de) 1988-09-06 2003-07-17 Pharmacia Ab, Stockholm Prostaglandinderivate zur Behandlung des grünen Stars oder einer okularen Hypertension
US5767154A (en) 1991-02-07 1998-06-16 Allergan 5-trans-prostaglandins of the F series and their use as ocular hypotensives
US5352708A (en) * 1992-09-21 1994-10-04 Allergan, Inc. Non-acidic cyclopentane heptanoic acid, 2-cycloalkyl or arylalkyl derivatives as therapeutic agents
US5385945A (en) 1992-10-21 1995-01-31 Allergan, Inc. 7-(5-substituted cyclopentyl) and (5-substituted cyclopentenyl) heptyl alcohols, heptylamines and heptanoic acid amides, and method of lowering intraocular pressure in the eye of a mammal by administration of these novel compounds
US5510383A (en) * 1993-08-03 1996-04-23 Alcon Laboratories, Inc. Use of cloprostenol, fluprostenol and their salts and esters to treat glaucoma and ocular hypertension
CA2274708A1 (en) 1997-10-13 1999-04-22 R-Tech Ueno, Ltd. Remedial composition for intraocular hypertension or glaucoma
US6066671A (en) 1997-12-19 2000-05-23 Alcon Laboratories, Inc. Treatment of GLC1A glaucoma with 3-benzoyl-phenylacetic acids, esters, or amides
AU8474701A (en) 2000-08-07 2002-02-18 Univ Vanderbilt Compositions and methods for detecting and quantifying cox-2 activity and 2-arachidonylglycerol metabolites

Similar Documents

Publication Publication Date Title
JP2022539089A5 (enExample)
CA2526534A1 (en) Compounds and methods for delivery of prostacyclin analogs
JP2024504932A5 (enExample)
JP2022551185A5 (enExample)
JP2018524339A5 (enExample)
US8501793B2 (en) Blood flow promoters for cauda equina tissues
JP2023553835A5 (enExample)
JP2010514786A5 (enExample)
JP2009523841A5 (enExample)
RU2014121090A (ru) Модуляторы рецептора нмда и их применение
RU99103617A (ru) Новые пара-терфенильные соединения
JP2009536660A5 (enExample)
KR920021578A (ko) 포스프노/비아릴 치환된 디펩티드 유도체
JP2004530641A5 (enExample)
CA2468412A1 (en) 17.alpha.-alkyl-17.beta.-oxy-estratrienes and intermediates for their production, use of the 17.alpha.-alkyl-17.beta.-oxy-estratrienes for the production of pharmaceutical agents as well as pharmaceutical preparations
JP2012511023A5 (enExample)
JP2022533069A5 (enExample)
JP2006528700A5 (enExample)
JP2003506491A5 (enExample)
JP2014505017A5 (enExample)
JP2008512408A5 (enExample)
JP2004507521A5 (enExample)
JPWO2020004649A5 (enExample)
JP2003107710A5 (enExample)
JP2002539181A5 (enExample)